MabVax Therapeutics and Telik have agreed to merge under an all-stock transaction to form a single organization that will focus on developing immunotherapy-based products for cancer diagnosis and treatment. Telik will be known as MabVax Therapeutics Holdings. "Through this transaction we hope to expand our current clinical platform as we pursue our lead monoclonal antibody product, 5B1, and clinical stage cancer vaccine programs," MabVax President and CEO J. David Hansen said.

Related Summaries